Severe asthma in obese patients: what to expect with Mepolizumab?

Fonseca, Ana; Machado, Daniela; Pascoal, Ivone; Franco, Inês; Lima, Ricardo

doi:10.1183/13993003.congress-2022.3216

Cited by 2 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study showed a significant reduction in the number of exacerbations in both populations, health-related quality of life, and asthma control independent of obesity ( Da Cunha Fonseca et al, 2022 ). However, non-obese patients had significant lung function improvement compared to patients with obesity, which further reinforces the importance of obesity as a comorbid condition which needs to be intensively addressed in asthma patients ( Da Cunha Fonseca et al, 2022 ).…”

Section: Biological Therapies In Type-2 High Asthmamentioning

confidence: 75%

“…After administering mepolizumab for the duration of the study, the authors found no statistically significant difference between the two weight groups in any of the variables, except for FVC% predicted, which resulted in a greater improvement in non-obese patients ( Da Cunha Fonseca et al, 2022 ). This study showed a significant reduction in the number of exacerbations in both populations, health-related quality of life, and asthma control independent of obesity ( Da Cunha Fonseca et al, 2022 ). However, non-obese patients had significant lung function improvement compared to patients with obesity, which further reinforces the importance of obesity as a comorbid condition which needs to be intensively addressed in asthma patients ( Da Cunha Fonseca et al, 2022 ).…”

Section: Biological Therapies In Type-2 High Asthmamentioning

confidence: 91%

Section: Anti-il-5 and Anti-il5rαmentioning

confidence: 96%

“…Interestingly, this analysis showed that varying the amount of the treatment (mepolizumab doses of 75, 100, 250 or 750 mg IV) resulted in similar exacerbation rate reductions across BMI categories with no discernible trend noted in exacerbation reductions with the 250 mg and 750 mg IV doses of mepolizumab, even at the higher weight categories ( Albers et al, 2019 ). Similarly, Fonseca et al examined a similar effect in an experiment conducted for 12 months including a total of 25 patients, with 11 patients exhibiting obesity ( Da Cunha Fonseca et al, 2022 ). After administering mepolizumab for the duration of the study, the authors found no statistically significant difference between the two weight groups in any of the variables, except for FVC% predicted, which resulted in a greater improvement in non-obese patients ( Da Cunha Fonseca et al, 2022 ).…”

Section: Biological Therapies In Type-2 High Asthmamentioning

confidence: 99%

“…Similarly, Fonseca et al examined a similar effect in an experiment conducted for 12 months including a total of 25 patients, with 11 patients exhibiting obesity ( Da Cunha Fonseca et al, 2022 ). After administering mepolizumab for the duration of the study, the authors found no statistically significant difference between the two weight groups in any of the variables, except for FVC% predicted, which resulted in a greater improvement in non-obese patients ( Da Cunha Fonseca et al, 2022 ). This study showed a significant reduction in the number of exacerbations in both populations, health-related quality of life, and asthma control independent of obesity ( Da Cunha Fonseca et al, 2022 ).…”

Section: Biological Therapies In Type-2 High Asthmamentioning

confidence: 99%

See 4 more Smart Citations

Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity

Garg,

Que,

Ingram

2024

Front. Pharmacol.

View full text Add to dashboard Cite

Over 20 million adults and 6 million children in the United States (US) have asthma, a chronic respiratory disease characterized by airway inflammation, bronchoconstriction, and mucus hypersecretion. Obesity, another highly prevalent disease in the US, is a major risk factor for asthma and a significant cause of diminished asthma control, increased submucosal eosinophilia, and reduced quality of life. A large subgroup of these patients experiences severe symptoms and recurrent exacerbations despite maximal dosage of standard asthma therapies. In the past two decades, the development of biological therapies has revolutionized the field and advanced our understanding of type 2 inflammatory biomarkers. However, patients with obesity and comorbid asthma are not principally considered in clinical trials of biologics. Large landmark cluster analyses of patients with asthma have consistently identified specific asthma phenotypes that associate with obesity but may be differentiated by age of asthma onset and inflammatory cell profiles in sputum. These patterns suggest that biologic processes driving asthma pathology are heterogenous among patients with obesity. The biological mechanisms driving pathology in patients with asthma and comorbid obesity are not well understood and likely multifactorial. Future research needs to be done to elicit the cellular and metabolic functions in the relationship of obesity and asthma to yield the best treatment options for this multiplex condition. In this review, we explore the key features of type 2 inflammation in asthma and discuss the effectiveness, safety profile, and research gaps regarding the currently approved biological therapies in asthma patients with obesity.

show abstract

Section: Biological Therapies In Type-2 High Asthmamentioning

confidence: 75%

Section: Biological Therapies In Type-2 High Asthmamentioning

confidence: 91%

Section: Anti-il-5 and Anti-il5rαmentioning

confidence: 96%

Section: Biological Therapies In Type-2 High Asthmamentioning

confidence: 99%

Section: Biological Therapies In Type-2 High Asthmamentioning

confidence: 99%

See 3 more Smart Citations

Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity

Garg,

Que,

Ingram

2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Weighted Breaths: Exploring Biologic and Non-Biologic Therapies for Co-Existing Asthma and Obesity

Pilkington,

Buragamadagu,

Johnston

2024

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Purpose of Review To discuss the effectiveness of biologics, some of which comprise the newest class of asthma controller medications, and non-biologics in the treatment of asthma co-existing with obesity. Recent Findings Our review of recent preliminary and published data from clinical trials revealed that obese asthmatics respond favorably to dupilumab, mepolizumab, omalizumab, and tezepelumab, which are biologics currently indicated as add-on maintenance therapy for severe asthma. Furthermore, clinical trials are ongoing to assess the efficacy of non-biologics in the treatment of obese asthma, including a glucagon-like peptide-1 receptor agonist, a Janus kinase inhibitor, and probiotics. Summary Although many biologics presently indicated as add-on maintenance therapy for severe asthma exhibit efficacy in obese asthmatics, other phenotypes of asthma co-existing with obesity may be refractory to these medications. Thus, to improve quality of life and asthma control, it is imperative to identify therapeutic options for all existing phenotypes of obese asthma.

show abstract

Severe asthma in obese patients: what to expect with Mepolizumab?

Cited by 2 publications

References 0 publications

Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity

Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity

Weighted Breaths: Exploring Biologic and Non-Biologic Therapies for Co-Existing Asthma and Obesity

Contact Info

Product

Resources

About